4 Stocks in Which FIIs Increased Their Stake in June 2026 Quarter

#2 IOL Chemicals & Pharmaceuticals

Most people have never heard of IOL, yet there's a good chance a painkiller in their medicine cabinet contains something made by the company.

Based in Ludhiana, Punjab, IOL is the world's largest producer of ibuprofen, with an estimated market share of around one-third of global ibuprofen production.

Along with pharmaceuticals, it operates a chemicals business focused on ethyl acetate and acetic anhydride. The company has steadily expanded into other active pharmaceutical ingredients (APIs), such as paracetamol and metformin, to lessen its reliance on ibuprofen alone.

The March 2026 quarter was the company's best on record. Revenue increased by 17% year on year to an all-time high.

EBITDA margin rose to over 15% and profit after tax jumped by 68%, aided by a better product mix and stronger contributions from the non-ibuprofen portfolio.

Management noted that ibuprofen demand has stabilized after an earlier period of overstocking, while paracetamol capacity utilization is expected to increase sharply this year.

In Q1 FY27, FII holding in IOL also increased.

For a company that has spent years focusing on a single product, this level of foreign buying suggests that the diversification effort is starting to gain credibility with global investors.

#3 Capri Global Capital

Capri Global is a non-banking financial company focused on secured lending, including gold loans, loans to small and medium enterprises, construction finance, and housing loans through its subsidiary, Capri Global Housing Finance.

The company's lending book is largely secured, with loans backed by collateral, which is partly why the business has grown quickly without compromising asset quality.

FY26 was a breakout year. Consolidated assets under management grew 60% to Rs 366 billion (bn), driven by a more than doubling of gold loans.

Profit after tax nearly doubled as well, helped by a lower cost-to-income ratio and improving spreads. Gross bad loans fell below 1% of the total, a figure most lenders growing this quickly would struggle to maintain.

Management has projected AUM of around Rs 460 bn by FY27, with gold loans eventually making up half of the portfolio.

In Q1 FY27, FII holding in Capri Global continued its upward trend.

Rapid AUM growth at an NBFC typically involves a compromise in asset quality. Capri Global's success in growing while managing bad loans is likely attracting foreign investors consistently.

#4 Granules India

Granules is a pharmaceutical company based in Hyderabad that produces APIs, pharmaceutical formulation intermediates, and finished dosages, covering the entire chain from raw drug ingredients to tablets.

Finished dosages now account for close to three-quarters of revenue, representing a shift that has taken the company up the value chain away from being a pure commodity API supplier.

FY26 was a record year, with revenue increasing by 20% and profit rising nearly 19% on a consolidated basis. The March 2026 quarter saw revenue climb 23% and EBITDA shoot up 40%.

A newer peptide manufacturing business, established through the Ascelis acquisition, became profitable at the EBITDA level during the year and could emerge as a fourth growth driver alongside APIs, intermediates, and finished dosages.

One concern is an upcoming US FDA re-inspection at the company's Gagilapur facility, which is delaying approvals for several new products until it is resolved.

In the June 2026 quarter, FII holding in Granules India increased.

Granules is the largest and most established name on this list, though it saw the smallest percentage increase. However, a rise of this size in a stock already well owned by foreign investors, highlights how the peptide strategy and the finished-dosage shift are being perceived.

Should You Follow FIIs Into These Stocks?

Four very different businesses, a drone maker, a pharma-chemicals company, an NBFC, and a pharmaceutical manufacturer, and one common thread: each is now being taken more seriously by a wider foreign shareholder base than it was six months ago.

None of these stocks is a straightforward bet on a single theme.

IdeaForge rides on India's defence budget, IOL rides on a decades-old pain-relief molecule finding new life through diversification, Capri Global rides on India's appetite for secured retail credit, and Granules rides on the country's position as a low-cost pharma manufacturer to the world.

What connects them is that each business showed something worth noticing in its numbers just before the foreign buying showed up.

That said, a rising FII stake is a signal, not a scorecard. It tells you where informed capital is choosing to sit. It doesn't tell you whether the price is right for you today, or whether your time horizon matches theirs.

So do your homework. Check the valuations and the corporate governance. Ask whether the growth story can actually hold up before you consider any investment.

Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such. Learn more about our recommendation services here...